Rahul V. Parghane - Concepedia

Author

Rahul V. Parghane

Tata Memorial Hospital

Also Known As

Rahul Parghane, Rahul V Parghane, Rahul V. Parghane, Rahul Vithalrao Parghane

Publications

839

Citations

H-Index

Concepts

All Affiliations

Tata Memorial Hospital Homi Bhabha National Institute Bhabha Atomic Research Centre Post Graduate Institute of Medical Education and Research Advanced Centre for Treatment, Research and Education in Cancer

About

Rahul V. Parghane is an author at Tata Memorial Hospital specializing in medicine, pathology, and radiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	121
2	Pathology	5	5	110
3	Health Sciences	2	2	37
4	Pharmacology	1	1	11
5	Surgical Oncology	1	1	44

Rahul V. Parghane

Publications

514

Citations

H-Index

Page 1

	Year	Citations
Clinical utility of <sup>177</sup>Lu‐DOTATATE PRRT in somatostatin receptor‐positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity Rahul V. Parghane, Chinna Naik, Sanjay Talole, Head & Neck	2019	66
Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort Sonam Suman, Rahul V. Parghane, Amit Joshi, British Journal of Radiology	2019	57
Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE Rahul V. Parghane, Sanjay Talole, Kumar Prabhash, Clinical Nuclear Medicine	2017	55
Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant <sup>177</sup>Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors Rahul V. Parghane, Manish Bhandare, Vikram Chaudhari, Journal of Nuclear Medicine	2021	47
Long-term outcome of “Sandwich” chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease Rahul V. Parghane, Vikas Ostwal, Anant Ramaswamy, European Journal of Nuclear Medicine and Molecular Imaging Surgical Oncology“ SandwichNovel Treatment StrategyMalignant DiseaseMedicine	2020	44
Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors Rahul V. Parghane, Sanjay Talole, Sandip Basu World Journal of Nuclear Medicine	2019	31
Long-term outcome of indigenous 177Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting Keerti Sitani, Rahul V. Parghane, Sanjay Talole, British Journal of Radiology	2020	30
Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant <sup>18</sup>FDG Uptake Vikas Ostwal, Sandip Basu, Prabhat Bhargava, Neuroendocrinology	2020	22
Multiple brown tumors caused by a parathyroid adenoma mimicking metastatic bone disease from giant cell tumor Rohit Phulsunga, Rahul V. Parghane, Rajendra Kanojia, World Journal of Nuclear Medicine 99Mtc-mibi Whole BodyBrown TumorMedicineSurgical PathologyGiant Cell Tumor	2015	21
Combined <sup>177</sup>Lu‐PSMA‐617 PRLT and abiraterone acetate versus <sup>177</sup>Lu‐PSMA‐617 PRLT monotherapy in metastatic castration‐resistant prostate cancer: An observational study comparing the response and durability Sonam Suman, Rahul V. Parghane, Amit Joshi, The Prostate	2021	20

Page 1